Cellics Therapeutics is a San Diego-based biopharmaceutical company that utilizes the innovative Cellular Nanoparticle (CNP) technology to develop nano-therapeutics and advance drug delivery for various substances such as mRNA, siRNA, proteins, and small molecules. Founded by UC San Diego Professor Liangfang Zhang, Cellics leverages two dynamic nanoplatforms, the Cellular Nanosponge and the Cellular Nanoparticle drug delivery technology, which harness the power of cell membranes to create specialized nanoparticle-based therapeutics with the potential to address a wide range of diseases.
The Cellular Nanosponge platform consists of a nanoparticle core coated with intact cell membrane, retaining surface protein receptors that mimic innate cells and can act as decoys to bind and neutralize bacterial toxins, cytokines, and viruses. The Cellular Nanoparticle drug delivery technology enables targeted and intracellular delivery of substances, offering high drug loading capacity, targeted drug delivery, intracellular delivery, and potentially improved safety profiles.
Generated from the website